Cannasat Therapeutics and IntelGenx Corp. Reach Key Milestone
TheNewsWire.ca, September 17, 2021
TORONTO – Cannasat Therapeutics Inc. (“Cannasat”) (TSX-V: CTH), a company specializing in the development of cannabinoid-based pharmaceutical products, announced today the commencement of a Phase 1 clinical study of its lead product, CAT 310, a potential treatment for neuropathic pain.
This Phase 1 trial is a randomized, single dose, crossover study comparing two different formulations of the drug in normal healthy male volunteers. The primary objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of the CAT 310 prototypes. This Phase 1 clinical study is being carried out at a single centre in Mississauga, Ontario.
Umar Syed, Cannasat’s Chief Scientific Officer, said, “The evidence for CAT 310 is compelling as a potential treatment for neuropathic pain, and we are pleased to be advancing this product into clinical trials. Today is an important milestone for Cannasat, as it marks the first human trial of CAT 310. This milestone also validates our decision in November 2006 to sign a long-term collaborative agreement with our development partner IntelGenx Corp. Without the hard work and dedication of the IntelGenx team, we would not be able to start this Phase 1 study on time and within budget.”
Neuropathic pain is associated with nerve damage and can be an especially difficult condition to treat, often requiring the use of strong narcotics that can cause serious adverse effects. This condition is caused by many common diseases such as diabetes, herpes zoster, HIV/AIDS, multiple sclerosis, and other causes of chronic pain. Most patients require treatment with multiple drugs and often achieve only partial relief. It is estimated that over 15 million people suffer from some variety of neuropathic pain in North America and Europe.
About Cannasat Therapeutics
Founded in 2004, Cannasat is an early stage pharmaceutical research and development company. Cannasat is developing cannabinoid-based pharmaceutical products using proprietary formulation and drug delivery technologies. Cannabinoids have broad therapeutic applications which are believed to include the treatment of neuropathic pain, chronic pain, depression, anxiety and movement disorders. More information about Cannasat (TSX-V: CTH) is available at www.cannasat.com.
About IntelGenx Corp.
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx has developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The company’s research and development pipeline includes products for the treatment of osteoarthritis, pain management, smoking cessation, and seasonal affective disorder. More information about IntelGenx is available at www.intelgenx.com.
Contact Information
Cannasat Therapeutics Inc.
Andrew Williams
Chief Operating Officer
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]
www.cannasat.com
Forward Looking Statements
Certain statements in this release may constitute forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors, which may cause actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements.
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.
